logo

For the Inventor, By the Inventor

Monmouth Junction, NJ, United States of America

Paul David Leeson

USPTO Granted Patents = 13

Average Co-Inventor Count = 3.7

ph-index = 6

Forward Citations = 131(Granted Patents)


Location History:

  • Monmouth Junction, NJ (US) (1997 - 1998)
  • Melbourne, GB (1998 - 1999)
  • Princeton, NJ (US) (1999)
  • Congerstone, GB (2001 - 2002)

Company Filing History:

goldMedal12 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal1 out of 1 
 
Merck & Dohme Limited
 patent

Years Active: 1997-2002

Loading Chart...
13 patents (USPTO):Explore Patents
1. 6352994 - Substituted 1H-pyridinyl-2-ones as GABAA alpha 2/3 ligands (2002-03-05),
2. 6200982 - Substituted 1H-pyridinyl-2-ones as GABAA-&agr; 2/3 ligands (2001-03-13),
3. 5939436 - Five-membered heteroaromatic compounds as dopamine receptor subtype (1999-08-17),
4. 5861407 - Tetrahydropyridine derivatives as dopamine receptor subtype ligands (1999-01-19),
5. 5849765 - Tetrahydropyridine derivatives as dopamine receptor subtype ligands (1998-12-15),
6. 5814644 - Indole derivatives as dopamine D4 antagonists (1998-09-29),
7. 5763448 - Pyrmidine derivatives (1998-06-09),
8. 5712285 - Pyrrolo-pyridine derivatives (1998-01-27),
9. 5700802 - Furopyridine derivatives (1997-12-23),
10. 5684006 - Isoxazole and pyrazole derivatives as dopamine receptor subtype ligands (1997-11-04),
11. 5681836 - Methanesulfonate salts of antipsychotic benzofuran derivatives (1997-10-28),
12. 5665722 - Benzofuran derivatives as D.sub.4 receptor antagonists (1997-09-09),
13. 5614518 - Morpholine derivatives as dopamine receptor subtype ligands (1997-03-25),

Title: Paul David Leeson: Innovator in GABA Receptor Ligands

Introduction

Paul David Leeson, hailing from Monmouth Junction, New Jersey, is a notable inventor recognized for his contributions to the field of medicinal chemistry. With 13 patents to his name, he has made significant advancements, particularly in the area of compounds that target GABA receptors, which play a critical role in the treatment of central nervous system disorders.

Latest Patents

Among his most recent patents are the "Substituted 1H-pyridinyl-2-ones as GABAA alpha 2/3 ligands," which highlight compounds that are selective ligands for GABA receptors. These innovations are crucial in developing therapies for various disorders affecting the brain. His work on "Substituted 1H-Pyridinyl-2-ones as GABA-Alpha 2/3 ligands" further emphasizes their utility in the pharmaceutical landscape, showcasing the potential of these compounds in addressing neurological conditions.

Career Highlights

Taking strides in the pharmaceutical industry, Paul has been associated with prominent companies such as Merck Sharp & Dohme Corporation and Merck & Dohme Limited. His experience in these organizations has equipped him with a wealth of knowledge and expertise, enabling him to contribute meaningfully to innovative drug development.

Collaborations

Throughout his career, Paul has collaborated with esteemed colleagues, including Janusz Jozef Kulagowski and Neil Roy Curtis. These partnerships have played a vital role in enhancing the research and development initiatives he has led, further cementing his reputation as a key player in the field.

Conclusion

Paul David Leeson's work demonstrates a remarkable dedication to innovation within the pharmaceutical industry, particularly in the realm of GABA receptor ligands. His 13 patents reflect a commitment to improving treatments for central nervous system disorders, solidifying his legacy as a leading inventor in medicinal chemistry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…